- ►annals.org [PDF] NK Choudhry, J Avorn - Annals of internal medicine, 2005 - Am Coll Physicians In late 2004, the British government decided to allow a lipid- lowering agent to
be sold as an over-the-counter medication. In contrast, the US Food and Drug
Administration recently decided not to do so. The United States and other ... Cited by 15 - Related articles - All 4 versions
- ►adisonline.com [PDF] KJ Krobot, K Wenke, B Reichart - Pharmacoeconomics, 1999 - ingentaconnect.com 1 Outcomes Research Department, MSD Sharp & Dohme GmbH, Haar, Germany 2
Department of Cardiac Surgery, Munich Bogenhausen, Munich, Germany 3 Department
of Cardiac Surgery, University Hospital, Munich-Grosshadern, Munich, Germany Cited by 3 - Related articles - BL Direct - All 6 versions
I Shirakawa, M Sata, A Saiura, Y Kaneda, H … - Biomedicine & Pharmacotherapy, 2007 - Elsevier Accelerated coronary arteriosclerosis remains a major problem for the long-term
survival of cardiac transplant recipients. However, the pathogenesis of
transplant vasculopathy is poorly understood and there is no effective ... Cited by 6 - Related articles - All 4 versions
JD Lee, JR Morrissey, DP Mikhailidis, V Patel - Current Medical Research and Opinion®, 2005 - informahealthcare.com Background: Vascular complications are a major Vascular complicat Vascular
complications Vascular complications are Vascular complications are am ular
complications are a ma lar complications are a major r complications are a ... Cited by 16 - Related articles - All 5 versions
N Ogawa, I Koyama, T Shibata, T Watanabe, … - Transplant International, 1996 - interscience.wiley.com Abstract This study was designed to investigate the effects of pravastatin (Pr)
on accelerated coronary arteriosclerosis in transplanted hearts. The rabbit
hearts were transplanted to the recipients' neck heterotopi-cally, and ... Cited by 6 - Related articles - BL Direct - All 3 versions
KM Field - Pharmacotherapy, 2005 - PPI Cardiovascular disease is the leading cause of death among adults in the United
States, in Europe, and in much of Asia. Despite advances in primary prevention
of coronary artery disease, including early detection and treatment of ... Cited by 8 - Related articles - BL Direct - All 3 versions
AS Wierzbicki, DP Mikhailidis, TM Reynolds - The Lancet, 2003 - Elsevier Although conforming with the general rule of statin trials that coronary events
are reduced by 1% for every 1% reduction in LDL cholesterol concentration over a
hypothetical 5-year period, 3 PROSPER differs from previous pravastatin ... Cited by 9 - Related articles - All 6 versions
